For men: Merck's 9-valent HPV vaccine starts phase 3 clinical trials in China and plans to enroll 8,100 people

On October 11, the Insight database showed that Merck announced the launch of a phase 3 clinical trial for the first time in China to evaluate the protective efficacy, immunogenicity and safety of the nine-valent human papillomavirus vaccine (Jadaxiu 9) in Chinese men.

Clinical trial details (Insight)

From: Insight database (http://db.

Jiadaxiu 9 is currently the only nine-valent HPV vaccine approved in China.

The immunogenicity surrogate endpoint data provided by international multi-center clinical trials show that the vaccine can also be used for vaccination of girls aged 9 to 15 years, and clinical research on the population of 9 to 15 years old in China is still in progress

The batch issuance data of the China Inspection Institute shows that the number of nine-valent cervical cancer vaccines has increased significantly since its launch.

Epidemiological data show that the effective rate of two-valent and four-valent HPV cervical cancer prevention is about 70%, and the nine-valent rate increases to 90%, which is more popular

According to the Insight database, domestic nine-valent HPV vaccines are currently being developed by many companies

Phase 3 clinical trial of domestic 9-valent HPV vaccine

From: Insight database (http://db.